Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A KEITH

Showing results (761-770 of 918) with videos related to

Pageof 92
Sort By:
Cancer Cell|February 5, 2008
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignanciesMarta Chesi, Davide F Robbiani, Michael Sebag, et al.
BMC Genomics|September 6, 2012
Comparative genomics of Brachyspira pilosicoli strains: genome rearrangements, reductions and correlation of genetic compliment with phenotypic diversityLuke J Mappley, Michael L Black, Manal AbuOun, et al.
Blood Cancer Discovery|March 11, 2026
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed Refractory Multiple MyelomaRintu Sharma, Andree-Anne Pelland, Katherine Lajkosz, et al.
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Journal of Clinical Pharmacology|December 8, 2016
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple MyelomaYing Ou, Sameer Doshi, Anh Nguyen, et al.
Environmental Toxicology and Chemistry|September 8, 2010
Cytochrome P4501A biomarker indication of oil exposure in harlequin ducks up to 20 years after the Exxon Valdez oil spillDaniel Esler, Kimberly A Trust, Brenda E Ballachey, et al.
Journal of Medicinal Chemistry|December 10, 2016
Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA AmplificationJames R Beadle, Nadejda Valiaeva, Guang Yang, et al.
Conservation Biology : the Journal of the Society for Conservation Biology|July 11, 2025
Applying the IUCN Global Ecosystem Typology to classify, describe, and map ecosystems based on regional data and Indigenous knowledgeAlys R Young, Hugh F Davies, Margaret L Ayre, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2010
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myelomaDonna E Reece, Dan Sullivan, Sagar Lonial, et al.
Leukemia|January 31, 2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenanceShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
Pageof 92

Showing results (761-770 of 918) with videos related to

Sort By:
Pageof 92
Cancer Cell|February 5, 2008
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignanciesMarta Chesi, Davide F Robbiani, Michael Sebag, et al.
BMC Genomics|September 6, 2012
Comparative genomics of Brachyspira pilosicoli strains: genome rearrangements, reductions and correlation of genetic compliment with phenotypic diversityLuke J Mappley, Michael L Black, Manal AbuOun, et al.
Blood Cancer Discovery|March 11, 2026
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed Refractory Multiple MyelomaRintu Sharma, Andree-Anne Pelland, Katherine Lajkosz, et al.
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Journal of Clinical Pharmacology|December 8, 2016
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple MyelomaYing Ou, Sameer Doshi, Anh Nguyen, et al.
Environmental Toxicology and Chemistry|September 8, 2010
Cytochrome P4501A biomarker indication of oil exposure in harlequin ducks up to 20 years after the Exxon Valdez oil spillDaniel Esler, Kimberly A Trust, Brenda E Ballachey, et al.
Journal of Medicinal Chemistry|December 10, 2016
Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA AmplificationJames R Beadle, Nadejda Valiaeva, Guang Yang, et al.
Conservation Biology : the Journal of the Society for Conservation Biology|July 11, 2025
Applying the IUCN Global Ecosystem Typology to classify, describe, and map ecosystems based on regional data and Indigenous knowledgeAlys R Young, Hugh F Davies, Margaret L Ayre, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2010
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myelomaDonna E Reece, Dan Sullivan, Sagar Lonial, et al.
Leukemia|January 31, 2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenanceShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
Pageof 92